Prostate cancer surgery more costly for obese men

	Tweet

Being obese may increase the cost of surgery for men with prostate cancer—at least the more traditional forms of the procedure, a new study suggests.

Researchers found that among 629 prostate cancer patients at their center who had a radical prostatectomy—surgical removal of the prostate gland—obese men generally incurred greater costs.

The difference, the study found, came from higher costs for anesthesia and other services in the operating room.

However, while obesity was related to greater expenses from both traditional “open” surgery and minimally invasive laparoscopic, or “keyhole” surgery, it did not affect the price tag of robot-assisted laparoscopic surgery—a technique that, over the past decade, has become the predominate approach to prostate removal in U.S. hospitals.

Among patients who underwent traditional surgery, performed through a long abdominal incision, the typical cost for obese men was $4,885. That compared with $4,377 for all other men.

The pattern was similar when it came to traditional laparoscopic surgery—a less invasive procedure where the surgeon makes several small incisions to insert thin instruments, including a camera that provides a view inside the abdomen. Among study patients who had this surgery, the typical cost was $5,703 for obese men and $5,347 for their non-obese counterparts.

In contrast, weight did not appear to sway the costs of robot-assisted laparoscopic surgery, in which a surgeon sits at a computer console, controlling robotic “arms” that hold the surgical instruments.

The price tag for robotic surgery was $6,761 for obese men and $6,745 for thinner men, according to findings published in the urology medical journal BJU International.

However, while weight did not affect the costs of robotic prostate surgery, the procedure clearly is not a bargain for obese men, said Dr. Yair Lotan, the senior researcher on the study and an associate professor of urology at the University of Texas Southwestern Medical Center in Dallas.

In an interview, he pointed out that hospitals pay about $1.5 million for the robot and take on other costs—including service contracts that run in excess of $100,000 a year. And the charges for the surgery reflect that.

If one were to consider cost alone, Lotan said, “it would be very difficult to justify” choosing robot-assisted prostate surgery over open surgery for patients of any weight.

However, the researcher added, if robotic surgery is the choice anyway, the current findings suggest that a patient’s extra pounds will not lead to extra costs.

The findings are based on 629 men who underwent radical prostatectomy at the Texas center between 2003 and 2008. Of those patients, 156 had open surgery, 211 had laparoscopic surgery, and 262 had robot-assisted surgery.

In general, Lotan explained, prostate surgery is more technically difficult and time-consuming with obese patients. And with surgery in general, he added, obese patients tend to have higher risks of complications, such as wound infections and problems with anesthesia.

So it is not surprising that the costs of open surgery would be greater for obese prostate cancer patients than for their thinner counterparts, according to Lotan. But it is not clear why obesity affected the cost of standard laparoscopic surgery, but not that of the robot-assisted procedure, he said.

One possibility, Lotan noted, is that the robot maneuvers the surgical instruments more easily compared with a surgeon performing standard laparoscopy, shortening the surgical time. But he added that technical skill and speed are also very much dependent on the surgeon and his or her experience.

Indeed, Lotan and his colleagues point out, a limitation of this study is that patients were treated at a single medical center, and the findings may not be true of all institutions.

Still, Lotan said, the findings do underscore the impact that obesity can have on surgical costs. “I don’t think it’s a stretch to say that the obesity problem in the U.S. is getting worse by the day,” he said. “This study highlights the fact that there is an added cost of that.”

SOURCE: BJU International, online March 23, 2010.

RELATED STORIES:
Study links obesity to more agressive prostate cancer   Association of C-peptide concentration with prostate cancer incidence in a prospective cohort   Novel association between Parkinson’s disease and prostate cancer   Ack1 molecule stimulates the aggressive growth of prostate cancer   Sexual side effects from prostrate drug   Obese men less likely to get biopsy after PSA screening   CCNY researchers demonstrate effectiveness of contrast agent Cytate in detectcing prostate cancer   ‘Mismatched’ prostate cancer treatment more common than expected   Delay OK before radiation for prostate cancer   Fewer complications, better outcomes with robot-assisted prostate cancer surgery   Tall men at risk of early prostate cancer   Urine test may detect aggressive prostate tumors   Finnish researchers find a compound that prevents the growth of prostate cancer cells   New Prostate Cancer Ultrasound Treatment Shows Promise   PSA Predicts Treatment Success in Advanced Prostate Cancer   Prostate Cancer: Watchful Wait or Vaccinate?   Gene test could save men from prostate surgery   Prostate Cancer Risk Among Users of Finasteride and Alpha-Blockers   Prostate Cancer Surgeons “Feel” With Their Eyes   Pricier therapy no better for early prostate cancer   Prostate surgery risks lower at academic hospitals   Folic Acid Supplements Linked To Higher Risk Of Prostate Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]